CytRx Unveils Clinical Development Plan for Pipeline Assets Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor December 03, 2008 08:30 AM Eastern Standard Time ...

The revised clinical development plan sees the previous dose-finding element of the pivotal PARADIGME trial being expanded and integrated into the Phase 1/2 (Lymrit 37-01 ...

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications Business Wire Tue, Dec 31, 2024 ...

NES-ZIONA, Israel, June 20, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that its paediatric investigation plan for clinical development of its long-acting human ...

--Revive Therapeutics Ltd., a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update on the Company’ s ...